Three in five women aged 30 to 49 have never been screened for cervical cancer, according to new World Health Organization estimates.
The figures emerged as international health officials marked the World Day for the Elimination of Cervical Cancer on November 17, highlighting persistent global inequalities in access to human papillomavirus testing and immunization programs.
Access to human papillomavirus testing remains severely unequal across regions, the WHO estimates show. Only 2% of women in low- and middle-income countries were screened using human papillomavirus testing in the preceding five years. By contrast, high-income nations recorded a screening rate of 32% over the same timeframe.
RTÉ reported that updated WHO data recorded 604,000 new cases of cervical cancer and 280,000 deaths worldwide. Persistent infection by oncogenic types of human papillomavirus, primarily types 16 and 18, drives the development of these malignancies. While most infections resolve naturally through immune system action, high-risk persistence leads to precancerous lesions that can evolve into invasive cancer over several years.

Women who did not have the opportunity to receive HPV vaccination must not also miss out on cervical cancer screening and timely treatment.
— World Health Organization
- Primary Prevention: Vaccines target high-risk human papillomavirus types 16 and 18 and are recommended preferentially before sexual activity begins for both boys and girls.
- Complementary Screening: Pap tests and molecular human papillomavirus DNA testing identify precancerous changes early, serving a different function than vaccination.
- Therapeutic Advancements: Early surgical management can cure initial stages, while newer protocols incorporate pembrolizumab into chemoradiotherapy for advanced cases.
Countries are rolling out new policies and expanding public health services to accelerate progress toward the 2030 elimination targets. Brazil integrated human papillomavirus DNA testing into its public health system across 26 of its 27 federal units. Meanwhile, Cabo Verde’s Ministry of Health prepared to introduce organized testing on Boa Vista Island with technical support from the WHO and the Spanish Agency for International Development Cooperation.
Therapeutic options have evolved alongside screening initiatives. EKPA experts said that the KEYNOTE-A18 trial demonstrated significant improvements in overall survival when pembrolizumab was added to chemoradiotherapy for high-risk locally advanced disease. The KEYNOTE-826 study also showed survival benefits from adding pembrolizumab to chemotherapy, with or without bevacizumab, in persistent, recurrent, or metastatic cases expressing PD-L1.
| Global Strategy Target | WHO 2030 Goal |
|---|---|
| HPV Vaccination | 90% of girls fully vaccinated by age 15 |
| Systematic Screening | 70% of women screened by ages 35 and 45 |
| Therapeutic Management | 90% of women with precancer or invasive cancer treated |
Vaccination is contraindicated for individuals with a history of immediate hypersensitivity to any vaccine component or yeast. Available human papillomavirus vaccines do not treat existing infections or active disease, and vaccination does not replace routine cervical screening.
Patients experiencing unusual vaginal bleeding after sexual intercourse or menopause, persistent unusual discharge, or pelvic pain require immediate gynecological investigation. Early evaluation ensures timely intervention before precancerous lesions progress to invasive stages.
- World Health Organization. Global Strategy for the Elimination of Cervical Cancer as a Public Health Problem.
- The Lancet Global Health. New WHO Estimates on Cervical Cancer Screening Inequalities.
- EKPA Therapeutic Clinic, Alexandra Hospital. Clinical Updates on HPV Pathogenesis and Therapeutics.